Latin American Contract Research Organizations Set to Get More Local Outsourcing Opportunities

– Currently, multinational companies outsource a larger proportion of their clinical trials than local firms, finds Frost & Sullivan

SAO PAULO, April 7, 2015 /PRNewswire/ — As market penetration stood at only 64 percent in 2013, huge opportunities exist for contract research organizations (CROs) to expand their market share in Latin America (LATAM). Local contracts, which accounted for 21.6 percent of the total market size in 2013, will begin to contribute more to overall revenues. The local development of biosimilars, domestic pharmaceutical companies’ plans to increase the number of clinical trials to comply with regulations, and focus on geographic expansion will give rise to more local contracts for CROs in the region.



Photo –

New analysis from Frost & Sullivan, Latin American Contract Research Organization Market (, finds that the market earned revenues of $438.5 million in 2013 and estimates this to reach $661.3 million in 2019 at a compound annual growth rate of 7.1 percent. The study covers phase I, phase II, phase III and late phase clinical development as well as biostatistics, central laboratory services and data management. Health economics studies, a part of late phase trials, will gain significant traction in the coming years, since they are utilized while deciding which new molecules to include in the list of reimbursed drugs considered by public health services and private insurance plans.

For complimentary access to more information on this research, please visit:

“Multinational pharmaceutical companies tend to outsource about 70 percent of their trials by adopting either a fully outsourced or function-to-function model,” said Frost & Sullivan Healthcare Consultant Sanjeev Kumar. “However, local pharmaceutical companies have lower outsourcing rates that range from 50 to 70 percent in countries across LATAM.”

In Argentina and Brazil, regulatory issues have restrained clinical development, thereby dampening the prospects of CROs in the region. Bottlenecks in the Agencia Nacional de Vigilancia Sanitaria (ANVISA) submission and approval processes have meant that protocol approval takes 12 to 15 months in Brazil and an average of 6 months in Argentina.

In addition, limited outsourcing among big pharmaceutical clients that can conduct in-house R&D and clinical drug testing has restricted CRO market growth. Nevertheless, as large, well-established CROs have begun to use specialized research technologies that can cater to the rising demand for drug development, pharmaceutical clients’ reliance on in-house R&D is likely to reduce considerably. Along with this trend, the rise of innovative therapeutic options as well as the need for increased drug efficacy and safety will promote market development.

“In order to better serve and become the preferred partner of bio-pharmaceutical companies, CROs in LATAM must make an effort to expand their range of services,” noted Kumar. “Mergers and acquisitions with local CROs will be a cost-effective approach to achieve this end.”

Latin American Contract Research Organization Market is part of the Life Sciences ( Growth Partnership Service program. Frost & Sullivan’s related studies include: Global Diabetes Drug Delivery Market, Global CRO Market, Global Stem Cell Market, and Global Infectious Disease Diagnostics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Latin American Contract Research Organization Market

Francesca Valente
Corporate Communications – Latin America
P: +54 11 4777 5300
F: +54 11 4777 5300

Photo –

Resverlogix Receives Two Patents for RVX-208 in China

CALGARY, Alberta, April 7, 2015 /PRNewswire/ — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, “Compounds for the Prevention and Treatment of Cardiovascular Disease” was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, “Methods of Preparing Quinazolinone Derivatives” was granted until June 2029.

“These two additional patents build upon the growing intellectual property estate for our core asset, RVX-208. With our Chinese patent life extending out to June 2029, RVX-208 now has the necessary protection required for a regional licensing deal in China,” stated Donald McCaffrey, president and CEO of Resverlogix. Mr. McCaffrey added, “Resverlogix views the ever expanding Chinese pharmaceutical market as an attractive opportunity which aligns with our regional licensing strategy. We will continue our discussions with potential partners at the China Bio Partnering Forum in Shanghai next week.” On April 15th, Resverlogix is one of four selected Canadian companies who will be presenting at China Bio.

About RVX-208

RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer’s disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.

About Resverlogix

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit We can be followed on our blog at and via Twitter @Resverlogix_RVX.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of cardiovascular disease, Alzheimer’s disease, peripheral artery disease and chronic kidney disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: +1-403-254-9252

Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1-212 845 4251
Phone: +1-212-845-4272

SAFC Launches New EX-CELL® Advanced™ Products for Scalable, Efficient Biopharmaceutical Manufacturing

ST. LOUIS, April 7, 2015 /PRNewswire/ — Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC® Commercial (, the Company’s business unit providing products and services for use in regulated pharmaceutical and biopharmaceutical applications, has launched the EX-CELL® Advanced™ product line. Designed to address the needs of an evolving industry where speed to market is paramount, the new product line provides for increased performance, streamlines regulatory compliance, and offers the supply chain security needed in today’s biopharmaceutical environment.

The first EX-CELL Advanced product is the high-performing batch media system developed for a range of widely used industrial CHO cell lines, including SAFC’s proprietary CHOZN® cell line. During rigorous testing, the EX-CELL Advanced CHO Fed-batch System outperformed other commercially available equivalents by displaying significantly higher titers. Robust scale up and effortless adaptation offers those in biopharmaceutical development the opportunity to get their process up and running quickly and efficiently. Protein quality, another vital consideration in the development process, remains uncompromised.

“At SAFC we recognize our customers’ needs are constantly changing”, said Deb Stutz, Director of Biopharm Marketing. “Our team has utilized unique expertise in raw material science, understanding of process knowledge and decades of experience in cGMP manufacturing in development of the new EX-CELL Advanced line. We are delighted to launch this product in response to market needs for new levels of speed and performance, while continuing to provide the confidence of a secure and transparent supply chain.”

EX-CELL Advanced products are available now as catalog products in a range of pack sizes. To learn more or to make a purchase inquiry about the EX-CELL Advanced CHO Fed-batch System, visit

©2015 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich, SAFC, EX-CELL, EX-CELL Advanced and CHOZN are trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.

WuXi PharmaTech Lists Shares of Small-Molecule Manufacturing Subsidiary STA on New Third Board in China

SHANGHAI, April 2, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary SynTheAll Pharmaceutical Co. Ltd. (“STA”) has received approval from the National Equities Exchange and Quotations (“NEEQ”) in China to list its shares on the New Third Board, the over-the-counter (OTC) stock exchange in China. STA shares will be listed beginning April 3, 2015. WuXi does not currently plan to issue new STA stock to the public immediately upon listing. In March 2015, following receipt of required government approvals, WuXi agreed to sell a 5.55% stake in STA stock to members of STA management and WuXi management at a price based on a third-party appraisal of the STA equity value. This sale will be settled in early April for approximately $28 million in total cash consideration, with WuXi recognizing a related gain on the sale in the second quarter of 2015. Two thirds of the shares purchased by the management employees are subject to a lock-up, with 1/3 available for sale on the first anniversary of the listing date and another 1/3 available for sale on the second anniversary of the listing date.

STA provides process chemistry services and manufactures small-molecule advanced intermediates and APIs for customer use in preclinical and clinical trials and for marketed small-molecule drugs. Its operations are located in the Waigaoqiao Free Trade Zone and Jinshan, both in Shanghai, and in Changzhou. STA does not include WuXi’s biologics manufacturing business. STA’s business is significantly more capital intensive than WuXi’s laboratory services business and is in the process of building new facilities in Changzhou to increase its production capacity. STA filed this application to list on the New Third Board late last year to allow the flexibility to raise capital eventually from the Chinese capital markets to fund its future growth and to pursue potential mergers and acquisitions.

The New Third Board was established by the State Council in January 2013 as a national OTC stock exchange to supplement trading activities on the Shanghai and Shenzhen stock exchanges, including the related Growth Equity Market (GEM) exchanges. China’s GEM exchanges provide for trading of stock of growth companies that do not otherwise satisfy the requirements for listing on the main Shanghai and Shenzhen stock exchanges. The New Third Board provides a pricing mechanism for valuing a company’s stock. Policies are currently expected to be introduced in the second half of 2015 to enable NEEQ-registered companies to transfer to the GEM exchanges.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead are predictions about future events. Examples of forward-looking statements in this press release include statements about the public issuance of STA shares. Future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. WuXi may decide not to issue STA shares to the public in the near term or at all. Among other factors impacting WuXi’s ability to offer new shares in STA, these actions are subject to market conditions and various PRC exchange and regulatory approvals. WuXi and STA may not realize the anticipated benefits of the listing, with a number of related risks including: STA may be unable to raise cash in amounts sufficient to meet its cash needs, WuXi’s ownership interest in STA will be diluted to the extent STA shares are sold to third parties, WuXi management could become distracted, and the trading price of WuXi’s ADSs could become more volatile as a result of the trading price of STA’s shares and business developments. Additional information about these and other relevant risks can be found in our Annual Report on Form 20-F for the year ended December 31, 2014 (expected to be filed in April 2015). The forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by law.

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
+1 (201) 585-2048

Aaron Shi
Director of Corporate Communications

To view the original version on PR Newswire, visit:

Novogen Engages Leading US Investor Relations Firm

SYDNEY, April 2, 2015 /PRNewswire/ — Novogen Ltd (ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company’s investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

Dr Graham Kelly said: “The investment community has reacted positively in recent times to the Company’s extensive drug discovery program and with significant growth in activity ahead in the short-term, we felt it was timely to appoint an advisory firm to build on that momentum and communicate our activities to the market to maximise shareholder value.  Showcasing the Company to the wholesale investment community is a key part of our strategy to bring new investors into the stock through on-market buying. We look forward to working with the PCG team.”

Jeff Ramson, Founder and CEO of PCG stated, “We are excited to work with the entire team at Novogen.  We have extensive experience with Australian emerging growth companies that have stakeholders on several continents.  We look forward to communicating the Novogen story to a larger group of US investors, who need to learn about their drug technology platforms and how management will execute the Company’s strategy in the short and long term. We look forward to the partnership.”


Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier capital markets advisory services, strategic investor relations, tactical digital and social media communications and cutting edge media and public relations for public and privately held companies. The team at PCG has extensive experience with life sciences and healthcare, high technology, metals and mining, financial services and emerging growth companies from around the globe.

PCG’s Capital Markets Advisory Services include overall investor relations’ strategy development to increase and leverage investor awareness, visibility and credibility. PCG’s Social and Digital Media services include leveraging social and professional digital media sites to effectively and accurately communicate client stories. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail, institutional investors, bankers and analysts using proprietary techniques, search engine optimization, online marketing, website development and our proprietary and extensive distribution network. PCG’s Media and Public Relations services are a strategic and integral component of all Corporate Communications. The media and public relations team works with print, broadcast, online news sites and bloggers to communicate the best client story at the right time. PCG also actively assists clients during the pre- and post-IPO process as well as through mergers, acquisitions, uplistings, and or a potential crisis. Communicating the client’s story accurately and effectively is tantamount to maximizing exposure to its current and potential stakeholders.

About Novogen Limited

Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’).  The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).  SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells.  The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubule drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton.  Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

+61 (0) 2 9472 4111

Investment Banker Appointed CEO of Australian Health Tech Start-Up

Australian start-up, Sonoa Health, has today appointed a respected investment banker as CEO. His mission: bring an innovative product to market, secure strategic partnerships, and expand internationally

SAN FRANCISCO, March 31, 2015 /PRNewswire/ — Sonoa Health, a health tech startup based in Melbourne, Australia, has developed a world-first consumer health portal, Health&, which brings together data from online health records, medication prescriptions, wearable devices and more.

Today, the Company appointed respected investment banker John Stewart as its CEO, who brings to the table more than 18-years experience in investment banking and corporate advisory, which has included working closely with the biggest names in Silicon Valley in the US.

Sonoa Health’s Founder and Chair, Mr Bob Biddle, said Mr Stewart’s appointment is a significant achievement for the Company, which was officially founded four years ago and ramped up production for its consumer health portal early last year with more than 50 handpicked recruits. The portal will be launched later this year.

“We are in a very exciting phase of our development and John’s appointment is a testament to the quality of the company we’ve built and the talent we’ve attracted to drive its success. We are delighted to welcome him to the team,” said Mr Biddle.

“John has spent more than a decade in the heartland of digital health in Silicon Valley and will contribute invaluable perspectives to our business as we secure strategic business partnerships, raise capital, launch our product, and expand internationally.”

Sonoa Health’s new CEO isn’t hesitating to embrace the challenge.

“Sonoa Health presents a rare opportunity to work with the very best medical, creative and digital minds, and has enormous potential for global growth. After more than 18-years in banking, I am pretty comfortable navigating risk and reward – and I know we’re in for an exhilarating climb here,” said Mr Stewart.

Sonoa Health is taking an astute step forward in the highly saturated health tech market, by engaging the world’s most respected medical pioneers to drive the development of health technology and education resources.

“Our Health& portal is designed to provide an intelligent interface between doctors and consumers, which displays consumer health information in one place and helps them to proactively manage illness. It is supported by a search engine containing animated, illustrated and written health content, which is derived from evidence-based resources and designed to boost health literacy,” said Mr Biddle.

“The unique algorithms at the core of Health& power a reasoning engine, which brings the logic of a doctor’s brain online and delivers truly individualised health information to consumers. To achieve this, we’ve accessed the brightest brains and harvested their knowledge.”

The Company has engaged nine medical professors, who are all members of the Order of Australia, to head its Medical Advisory Board. In-house, there is a bright young team of doctors, writers, developers, animators, illustrators and an entrepreneurial leadership team too.

“It’s heartening to lead a brave and committed team of individuals, who are so focused on improving lives across the world. The launch of the Health& consumer portal later this year will signal a great achievement for Australia’s innovation sector,” said Mr Stewart.

Prior to joining Sonoa Health, Mr Stewart was a Managing Director at Gresham Partners, a Managing Director with Lazard in Australia and spent more than 11 years in the US in M&A roles with JPMorgan and Thomas Weisel Partners.He has also worked as an M&A lawyer with Fried Frank in New York and Corrs in Australia.

For more information about Health& visit

Media Interviews:

To request an interview with Sonoa Health CEO, John Stewart, please contact Chief Communications Officer, Haley Price, on +61-423-139-163

Links & Resources:

* Photos of CEO John Stewart and the Sonoa Health team may be downloaded:

Photo 1 [ ] and Photo 2 [ ]

* A video showcasing the Health& consumer portal is available HERE –

* Further resources are available upon request

Visit the Sonoa Health corporate website [ ]

To view the original version on PR Newswire, visit:

Yale University and Novogen Release Data on Cantrixil Mode of Action

Key data confirming Cantrixil kills ovarian cancer stem cells

Unique action of inhibiting pro-survival mechanisms and promoting pro-death mechanisms

SYDNEY, March 30, 2015 /PRNewswire/ — US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN) and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.

In both in vitro and in animal studies, Cantrixil, has proved highly effective at killing human ovarian stem (tumor-initiating) cells, cells that otherwise are highly resistant to standard of care cytotoxic drugs and which generally are believed to be responsible for diseases recurrence following initial therapy. Researchers have been keen to understand how the active ingredient in Cantrixil, TRXE-002, is able to achieve this effect where other drugs have failed.

The data shows that Cantrixil specifically activates the JNK-Jun pathway leading to mitochondrial damage and the induction of genes associated with cell death (apoptosis). In addition, Cantrixil blocks the survival pathway pERK.  The combination of these two cellular effects (down-regulation of pro-survival and up-regulation of pro-death pathways) provides a unique advantage to target chemo-resistant cancer stem cells.

Cantrixil is due to enter its first-in-man study in late-2015.  The study will enroll patients with the terminal condition, malignant ascites, associated with late-stage abdominal carcinomatosis of various types of cancer, but mainly targeting ovarian cancer and colo-rectal cancer.

About Cantrixil

Cantrixil is a cyclodextrin envelope containing the active ingredient, TRXE-002. The construct has been designed as an intra-cavity chemotherapy to be injected directly into the peritoneal and pleural cavities without causing local irritation or toxicity. Its purpose is to achieve high drug levels in the environment in which the cancer is spreading through the migration of the cancer stem cells are spreading. The ultimate primary indication of Cantrixil to be sought is first-line therapy of early-stage cancers of the abdominal cavity (eg. ovarian, uterine, colo-rectal and gastric carcinomas). Cantrixil will enter the clinic in later-stage cancers where the abdominal carcinomatosis has resulted in the terminal condition of malignant ascites.

Cantrixil is owned by CanTx, Inc.

About TRXE-002

TRXE-002 is a small molecule cytotoxic belonging to a family of compounds whose anti-cancer function is based on various biological effects including inhibition of trans-membrane electron-transfer mechanisms. TRXE-002 is pan anti-cancer acting, resulting in caspase-dependent apoptosis of both stem cell-like cancer cells and their daughter cancer cells. The compound has a high therapeutic index with little cytotoxic effect on non-tumor cells.

About CanTx, Inc.

CanTx is a joint venture company between Novogen and Yale University. Novogen has licensed the drug candidate, TRXE-002, to CanTx for use in Cantrixil. CanTx is based in New Haven, CT.

Further information is available on

About Novogen Limited

Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the cancer stem (tumor-initiating) cell.

The ATM compounds target the micro-filament component of the cancer cell’s cytoskeleton and have been designed to combine with anti-microtubule drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises two SBP drug candidates (TRXE-002, TRXE-009) and one ATM drug candidate (Anisina).

Further information is available on our website

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

+61 (0) 2 9472 4111

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as “expects,” “appear,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “should,” “would,”  “may,” “target,”  “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, Cantrixil and TRXE-002, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to Cantrixil and TRXE-002, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, Cantrixil and TRXE-002, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil and TRXE-002, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Biosafe Goes Direct in Brazil, Acquiring Its Local Distributor

EYSINS, Switzerland, March 30, 2015 /PRNewswire/ — After a successful partnership of 10 years with its local distributor ACTS do Brasil Ltda., effective immediately Biosafe has acquired all ACTS’ Biosafe-related business, which has been spun off into a separate operating entity, Biosafe Brasil Distribuidora Ltda. Terms have not been disclosed.

This move will allow Biosafe to offer an extended range of benefits to customers in Brazil, including direct product support and service.

Today most public and private cord blood banks throughout the country already process with Biosafe’s proprietary Sepax technology, which is also used by a number of customers for regenerative medicine applications.

Olivier Waridel, CEO of the Biosafe Group, commented: “We firmly believe in the potential of the Brazilian market and this acquisition will further expand our  business  in our core markets of stem cell banking, regenerative medicine and bioprocessing. We look forward to strengthening our relationship with existing and future customers, and to assisting them with their development.”

Elsewhere in Latin America, Biosafe products are sold through distributors in Mexico, Argentina, Colombia and Chile. Biosafe plans to extend the network to additional countries in the near future.

About the Biosafe Group   

Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and Sao Paulo) and is present in more than 50 countries, either directly or through distributors.

For further information:

Christopher Bolton
Biosafe Group SA

Investigational New Drug Application for WuXi MedImmune’s Monoclonal Antibody Accepted for Review by CFDA

SHANGHAI, March 27, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune’s novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration (CFDA).

In September 2012, MedImmune, the global biologics research and development arm of AstraZeneca, and WuXi AppTec formed the joint venture WuXi MedImmune Biopharmaceutical Co. Limited to develop and commercialize MEDI5117, a novel, investigational, long-acting monoclonal antibody for autoimmune and inflammatory diseases, the first such collaboration in China between a global company and a Chinese company to develop novel biologics. WuXi AppTec completed all CMC, nonclinical, and clinical sections of the dossier, and the wholly owned subsidiary of the joint venture filed an IND for it with the Jiangsu provincial FDA as a Class 1 therapeutic biologic in December 2014. WuXi AppTec’s biologics and pre-clinical facilities in Shanghai, Suzhou, and Wuxi passed the Jiangsu FDA’s onsite inspections in January 2015. The IND application has now been entered into the system of the CFDA for technical review. WuXi AppTec will continue to provide manufacturing for the program at its state-of-the-art biologics facilities, the first in China to meet cGMP standards of the United States, the European Union, and China, as well as provide local regulatory, pre-clinical, and clinical trial support.

“We are very pleased that our collaboration with MedImmune has advanced this important novel class 1 biologic on schedule,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “WuXi’s capabilities in integrated biologics discovery, development, and manufacturing offer a global platform with the highest quality standards. This initiative showcases WuXi’s capabilities as a gateway for developing novel biologics in China.”

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information on WuXi’s biologics services, please visit:

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
(201) 585-2048

Aaron Shi
Director of Corporate Communications
+86-21 5046-4362

To view the original version on PR Newswire, visit:

Finesse Solutions Announces Cellworld 2015

SANTA CLARA, Calif., March 26, 2015 /PRNewswire/ — Finesse Solutions announced Cellworld 2015, a new event that is specifically designed for innovators, visionaries and senior executives in bio-processing.

The two day conference, by invitation only, will be held at the Hyatt Regency in Downtown San Francisco on September 21-22, 2015.  It will be a forum for life science leaders to discuss the future of single-use biopharmaceutical manufacturing and to hear about both disruptive technologies and best practices from all facets of our industry.   

The event sessions will cover both upstream and downstream single-use bio-processing with a focus on innovation through the use of novel measurement and automation systems.  It will introduce new tools for managing process complexity and the resulting intelligent meta-data.  Topics will range from new single-use sensors to implementing commercial-off-the-shelf, highly configurable manufacturing execution systems (MES) for single-use facilities. 

“Our goal is to provide the senior leadership in bio-processing with a glimpse of the future in order to fully exploit single-use technologies and to remain globally competitive,” stated Barbara Paldus, CEO of Finesse Solutions. “We are very excited to create the first international forum to explore innovation and technology, so that as a community, we can accelerate the adoption of new bio-processing platforms and fully exploit highly intelligent tools that are rapidly becoming available through advances in electronics, software, and communications.” 

About Finesse Solutions, Inc.

Finesse Solutions provides flexible hardware and software automation which allows for unmatched customizable bioprocessing.  We are a research based, Silicon Valley company who believes in empowering our clients with innovative single-use sensors, bioreactors, controllers and software.  Our SmartParts are the foundation of a Finesse solution using technologies from inside and outside of the biopharmaceutical industry.  In addition to our own products, we are the only supplier with integration expertise offering clients the independence to select any preferred supplier of key unit operations from upstream to downstream.  Whether it’s a stand-alone, single-use bioreactor for research and development or a fully integrated Smartfactory for cGMP-compliant manufacturing, we have a bioprocess solution for our customers.  

For more information, please visit us at